Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459809 | 0.88 | RAB9A (0.40) | CHRM4NPC1RAB9ALMNAADORA2A | |
| SCHEMBL2079156 | 0.84 | RAB9A (0.54) | EGFRCHRM4NPC1RAB9ALMNA | |
| SCHEMBL5438380 | 0.79 | EGFR (0.51) | EGFRNPC1RAB9ASLC6A12ACKR3 | |
| SCHEMBL3389897 | 0.79 | MTNR1A (0.58) | EGFRCHRM4WDR5NPC1RAB9A | |
| SCHEMBL3395122 | 0.79 | MTNR1A (0.58) | EGFRCHRM4WDR5NPC1RAB9A | |
| SCHEMBL3802112 | 0.77 | MTNR1A (0.49) | EGFRWDR5NPC1RAB9ALMNA | |
| SCHEMBL2454974 | 0.77 | NPC1 (0.43) | NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL2458262 | 0.77 | RAB9A (0.57) | NPC1RAB9ASLC6A12SMN1; SMN2 | |
| SCHEMBL5431692 | 0.76 | RAB9A (0.60) | NPC1RAB9ALMNAACKR3ADORA2A | |
| SCHEMBL5423494 | 0.76 | RAB9A (0.60) | NPC1RAB9ALMNAACKR3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534277-B1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-09-14 | — | — | EP | disclosed |
| EP-1534277-B1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-09-14 | — | — | EP | disclosed |
| CN-100337626-C | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2007-09-19 | — | — | CN | disclosed |
| US-7105513-B2 | Cardiovascular disorders; strokes; hypotensive agents | SANOFI-AVERTIS DEUTSCHLAND GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| CN-1674895-A | Acylated, heteroaryl-fused cycloalkenylamines and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1534277-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| WO-2004014372-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | LIPG, AADAC, AANAT | EGFR 970/4885CHRM4 548/4885WDR5 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.